NEOGENOMICS INCNEOEarnings & Financial Report
NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.
Revenue
$172.0M
Gross Profit
$77.3M
Operating Profit
$-18.4M
Net Profit
N/A
Gross Margin
44.9%
Operating Margin
-10.7%
Net Margin
N/A
YoY Growth
10.6%
NEOGENOMICS INC Q4 FY2024 Financial Summary
NEOGENOMICS INC reported revenue of $172.0M (up 10.6% YoY) for Q4 FY2024, with a net profit of N/A (N/A margin). Cost of goods sold was $94.7M, operating expenses totaled $95.7M.
Key Financial Metrics
| Total Revenue | $172.0M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 44.9% |
| Operating Margin | -10.7% |
| Report Period | Q4 FY2024 |
NEOGENOMICS INC Annual Revenue by Year
NEOGENOMICS INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $727.3M).
| Year | Annual Revenue |
|---|---|
| 2025 | $727.3M |
| 2024 | $660.6M |
| 2023 | $591.6M |
| 2022 | $509.7M |
NEOGENOMICS INC Quarterly Revenue & Net Profit History
NEOGENOMICS INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $186.7M | +11.1% | $-108.0M | -57.9% |
| Q4 FY2025 | $190.2M | +10.6% | N/A | N/A |
| Q3 FY2025 | $187.8M | +11.9% | $-27.1M | -14.4% |
| Q2 FY2025 | $181.3M | +10.2% | $-45.1M | -24.9% |
| Q1 FY2025 | $168.0M | +7.5% | $-25.9M | -15.4% |
| Q4 FY2024 | $172.0M | +10.6% | N/A | N/A |
| Q3 FY2024 | $167.8M | +10.4% | $-17.7M | -10.5% |
| Q2 FY2024 | $164.5M | +12.0% | $-18.6M | -11.3% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $164.5M | $167.8M | $172.0M | $168.0M | $181.3M | $187.8M | $190.2M | $186.7M |
| YoY Growth | 12.0% | 10.4% | 10.6% | 7.5% | 10.2% | 11.9% | 10.6% | 11.1% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.64B | $1.64B | $1.64B | $1.60B | $1.39B | $1.37B | $1.36B | $1.35B |
| Liabilities | $727.4M | $732.9M | $735.7M | $713.2M | $539.9M | $536.5M | $523.3M | $517.8M |
| Equity | $915.9M | $908.2M | $902.3M | $888.3M | $854.0M | $838.3M | $836.6M | $828.8M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $13.9M | $9.2M | $9.8M | $-25.3M | $20.3M | $8.9M | $1.3M | $-8.1M |